Autosomal Dominant Polycystic Kidney Disease Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Autosomal Dominant Polycystic Kidney Disease Market is segmented By Mutation Type (PKD1 mutations, PKD2 mutations), By Therapeutics (Vasopressin V2 Re....
Autosomal Dominant Polycystic Kidney Disease Market Size
Market Size in USD
CAGR6.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.2% |
| Market Concentration | High |
| Major Players | Otsuka Pharmaceutical, Reata Pharmaceuticals, Xortx Therapeutics (XRx-008), Sanofi, Janssen Pharmaceuticals |
please let us know !
Autosomal Dominant Polycystic Kidney Disease Market Analysis
The Global Autosomal Dominant Polycystic Kidney Disease Market is estimated to be valued at USD 1.56 Bn in 2024 and is expected to reach USD 2.25 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Autosomal Dominant Polycystic Kidney Disease is a genetic disorder characterized by the growth of numerous cysts in the kidneys which can lead to kidney failure at an early age if left untreated. The increasing prevalence of the disease along with rising healthcare expenditures is expected to primarily drive the market growth over the forecast period.
The market has witnessed some positive trends over recent years. Research into new drugs and treatment options has increased substantially. Several pharmaceutical companies have drugs in late-stage clinical trials that could slow cyst growth or progression to kidney failure if approved. Increased awareness about the genetic nature of the disease has led to more families undergoing genetic screening and early detection. Early treatment can help preserve kidney function longer.